PHK
TSHA icon

Point72 Hong Kong’s Taysha Gene Therapies TSHA Stock Holding History

Point72 Hong Kong’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,890
Closed -$132K – 2049
2020
Q3 		$132K Buy
+5,890
New +$139K 0.01% 511

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Point72 Hong Kong's TSHA Position: Q4 2020 in Review

Point72 Hong Kong sold out of Taysha Gene Therapies (TSHA) in Q4 2020, closing a stake of 5,890 shares — an estimated $132K sold.

Point72 Hong Kong first reported a position in TSHA in Q3 2020 and held it in 1 quarter. The position peaked at $132K in Q3 2020. 51 funds tracked by Wall St. Rank hold TSHA as of Q4 2020.

  • Point72 Hong Kong reported no remaining Taysha Gene Therapies position as of Q4 2020 after selling out during the quarter.
  • Point72 Hong Kong sold 5,890 Taysha Gene Therapies shares in Q4 2020, an estimated $132K.
  • Point72 Hong Kong first reported a position in Taysha Gene Therapies in Q3 2020 and held it in 1 quarter.
  • Point72 Hong Kong's Taysha Gene Therapies position peaked at $132K in Q3 2020.
  • 51 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2020.

Based on Point72 Hong Kong's 13F filing for Q4 2020, filed 16 Feb 2021.